Biogen, Inc. (BIIB)
$278.14 6.07 (2.14%)
19:52 EST BIIB Stock Quote Delayed 15 Minutes
Previous Close $278.14
Market Cap 58.69B
PE Ratio 19.87
Volume (Avg. Vol.) 1.26M
Day's Range 277.32 - 284.99
52-Week Range 215.77 - 338.87
Dividend & Yield N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen, Inc. News
- From InvestorPlace
- From the Web
Wednesday's big stock charts highlight 3 stocks looking to break through resistance in a market that looks a bit shaky at the moment.
Value stocks are hot these days, and the best part is the shift toward them isn't stopping anytime soon. Here are five to buy today.
Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.
Options trading was buzzing in Biogen, McDonald's and Lyft stock on Tuesday. Here are the metrics that matter moving forward.
Biogen erupted in early trading, as it seeks approval for its Alzheimer's treatment. Here's what happened in the stock market today.
Another opioid settlement has been reached and earnings season is heating up. Here's what happened in the stock market today.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Biogen earnings for the second quarter of the year have BIIB stock heading higher on Tuesday thanks to a strong EPS and revenue beat.
The owners of Biogen stock will examine Biogen earnings to asss the progress that BIIB is making in key areas, including Ms and Spinraza.
Investors saw new highs in the Nasdaq today, but the index finished slightly lower on the day. Here's what we're watching now.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
Biotech rallied on a $63 billion deal between AbbVie and Allergan. But other than that, it was a tough day for the Nasdaq today.
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
If you’re looking for the next big thing in investing, these three down but not out biotech stocks are the way to go.
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
From The Motley Fool
From Market News Video
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (BIIB), where a total volume of 12,151 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 90.9% of BIIB's average daily trading volume over the past month, of 1.3 million shares..
From Analyst Ratings
Oppenheimer analyst Jay Olson maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $338.00. The company’s shares closed last Monday at $284.21. According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.4% and a 35.0%
Navellier RatingsPowered by Portfolio Grader